Drug Profile


Alternative Names: MY 309; SCH 376; ZK 76604

Latest Information Update: 06 Dec 2001

Price : $50

At a glance

  • Originator Bayer Schering Pharma; Mediolanum
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Mediolanum
  • Class Analgesics; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatic disorders

Most Recent Events

  • 06 Dec 2001 Discontinued-preregistration for Rheumatic disorders in USA (Unknown route)
  • 06 Dec 2001 Discontinued-preregistration for Rheumatic disorders in Germany (Unknown route)
  • 06 Dec 2001 Discontinued-II for Rheumatic disorders in Austria (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top